This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.
NGENLA is indicated for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone (GH). NGENLA is a long-acting GH with once-weekly dosing and may deliver a preferred treatment experience vs daily Genotropin. NGENLA is available with Pfizer-funded patient support and has a comparable cost to other daily GH options.1,2,3
Pfizer has been dedicated to supporting children with GH disorders, including paediatric GH deficiency, to achieve their growth potential for over 30 years.4
NGENLA administered once-weekly demonstrated significant reduction in treatment burden, greater patient convenience, greater intent to comply and greater patient preference compared with daily Genotropin (somatropin).1,2
Pfizer can support you in initiating your patients on NGENLA, whilst patients and caregivers can have peace of mind that they can continue to access Pfizer’s patient support programme.
Once-weekly dosing with NGENLA is achieved with C-Terminal Peptide (CTP) technology, extending the half-life of human Growth Hormone (hGH).
Somatrogon is composed of a human Growth Hormone molecule fused with C-terminal peptide (CTP) from naturally occurring human chorionic gonadotropin (hCG).1,5
• C-terminal peptides are naturally occurring peptides derived from the beta chain of hCG.5
• C-terminal peptides provide hCG with required longevity, but do not impact interaction with hCG and its receptor.5
• Like hGH, somatrogon binds to the GH receptor and initiates a cascade leading to changes in growth and metabolism.1
References:
Access practical support for initiating patients on NGENLA and learn more about patient preference for weekly dosing.
Access data on the efficacy and safety profile of NGENLA.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024